Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344: 1383–9.
2.
CannerPLBergeKGWengerNKStamlerJFreidmanLPrineasRJ. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol1986; 8: 1245–55.
3.
FrickMHEloOHaapaKHeinonenOPHeinsalmiPHeloP. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med1987; 317: 1237–45.
4.
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial, I. Reduction in incidence of coronary heart disease. JAMA1984; 251: 351–64.
5.
ShepherdJCobbeSMFordIIslesCGLorimerARMacfarlanePW. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med1995; 333: 1301–7.
6.
PhilbinEFPearsonTA. How does lipid-lowering therapy rapidly reduce ischemic events?J Myocard Ischemia1994; 6 (10): 13–8.
7.
LevineGNKeaneyJFJrVitaJA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med1995; 332: 512–21.
8.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA1993; 269: 3015–23.
9.
GeurianKL. The cholesterol controversy. Ann Pharmacother1996; 30: 495–500.
10.
FrickMHHeinonenOPHuttunenJKKoskinenPManttariMManninenV. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease: an ancillary study in Helsinki Heart Study frame population. Ann Med1993; 25: 41–5.
11.
SuperkoHRKraussRM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation1994; 90: 1056–69.
12.
JukemaJWBruschkeAVGvan BovenAJReiberJHCBalETZwindermanAH. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation1995; 91: 2528–40.
13.
BrownGAlbersJJFisherLDSchaeferSMLinJTKaplanC. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med1990; 323: 1289–98.
14.
WattsGFLewisBBruntJNHLewisESColtartJDSmithLDR. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet1992; 339: 563–9.
15.
EgashiraKHirookaYKaiHSugimachiMSuzukiSInouT. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation1994; 89: 2519–24.
16.
LeungWHLauCPWongCK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet1993; 341: 1496–500.
17.
TreasureCBKleinJLWeintraubWSTalleyJDStillabowerMEKosinskiAS. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med1995; 332: 481–7.
18.
AndersonTJMeredithITYeungACFreiBSelwynAPGanzP. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med1995; 332: 488–93.
19.
BradfordRHShearCLChremosANDujovneCDowntonMFranklinAF. Expanded clinical evaluation of lovastatin (EXCEL) study results, I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med1991; 151: 43–9.
20.
Product information. Lopid (gemfibrozil). Morris Plains, NJ: Parke Davis, Division of Warner-Lambert, 1994.
21.
VartiainenEPuskaPPekkanenJTuomilehtoJLonnqvistJEhnholmC. Serum cholesterol concentration and mortality from accidents, suicide, and other violent causes. BMJ1994; 309: 445–7.
22.
WeidnerGConnorSLHollisJFConnorWE. Improvements in hostility and depression in relation to dietary change and cholesterol lowering: the Family Heart Study. Ann Intern Med1992; 117: 820–3.
23.
EckernasSARoosBEKvidalPErikssonLOBlockGANeafusRP. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG-CoA reductase inhibitors in patients with primary moderate hypercholesterolemia. Br J Clin Pharmacol1993; 35: 284–9.
24.
VgontzasANKalesABixlerEOManfrediRLTysonKL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther1991; 50: 730–7.
25.
WysowskiDKGrossTP. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch Intern Med1990; 150: 2169–72.
26.
MuldoonMFManuckSBMatthewsKA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ1990; 301: 309–14.
27.
Committee of Principle Investigators. A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J1978; 40: 1069–118.
28.
DalenJEDaltonWS. Does lowering cholesterol cause cancer?JAMA1996; 275: 67–9.
29.
NewmanTBHulleySB. Carcinogenicity of lipid-lowering drugs. JAMA1996; 275: 55–60.
30.
KobashigawaJAKatznelsonSLaksHJohnsonJAYeatmanLWangXM. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med1995; 333: 621–7.
31.
LawMRThompsonSGWaldNJ. Assessing possible hazards or reducing serum cholesterol. BMJ1994; 308: 373–9.
32.
AdkinsDPsatyBMKoepsellTDLongstrethWTLarsonEB. Cholesterol reduction and the risk of stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med1993; 119: 136–45.
33.
ByingtonRPJukemaJWSalonenJTPittBBruschkeAVHoenH. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation1995; 92: 2419–25.
